SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT2) inhibitors induce ketosis in patients with diabetes mellitus type 2 (5.6 ± 6.0 μmol/L when fasting and 3.3 ± 3.8 μmol/L when fed), but not in patients without diabetes (35) and reduce the risk of cardiovascular death and hospitalization for heart failure in both groups (36, 37).